FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep

Emma Walmsley upholds £40B sales target in her final GSK CEO report Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. | Emma Walmsley and her ...

#GSK #EmmaWalmsley #LukeMiels #Blenrep #Arexvy #Shingrix #multiplemyeloma #PD1inhibitor #Jemperli #rectalcancer #antibodydrugconjugates #ADCs #HansohPharma #FDAapproval #longactingbiologic #depemokima #chronicrhinosinusitis #biologics #vaccines #shinglesvaccine #RSVvaccine
zurl.co/iumHW

As Blenrep returns, GSK adds another ADC to cancer pipeline GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.

#GSK #oncology #Blenrep #ADC #antibodydrugconjugates #prostatecancercandidate #Syndivia #advancedcastrationresistantprostatecancer #CRPC #mCRPC #multiplemyeloma #multiplemyelomaADC #prostatecancer #B7H3targetedADC #Hansoh #osteosarcoma #ESMO #GeminiMabconjugationtechnology
zurl.co/8KpGz

Against the odds, #GSK has secured FDA approval for its #multiplemyeloma therapy #Blenrep, three years after it was removed from sale.

pharmaphorum.com/news/gsks-bl...

Scotland approves new treatment option for multiple myeloma patients - PharmaTimes Blenrep combination offers improved survival for those ineligible for lenalidomide

#Haematology #Oncology #Scotland #NHSScotland #multiplemyeloma #GSK #Blenrep #belantamabmafodotin #Blenrepcombination #lenalidomide #ScottishMedicinesConsortium #SMC #bortezomibanddexamethasone #BVd #SMCrecommendation #phase3data #DREAMM7study #progressionfreesurvival
zurl.co/ydmDa

The State of Blenrep: What Patients Should Know - MMRF Updated 7/25/2025 Blenrep (belantamab mafodotin) has now been approved for use in both the European Union and Canada—clear signals that international health authorities recognize its clinical value an...

Blenrep has been approved in both the EU 🇪🇺 and Canada 🇨🇦—a meaningful step toward broader global access for myeloma patients.

In the U.S., the FDA review continues. Here’s what patients should know:

themmrf.org/mmrf-blogs/t...

#MultipleMyeloma #Blenrep #MMRF

Bonnes nouvelles sur le #MyélomeMultiple 🩸

Deux nouvelles thérapeutiques ont été approuvées dans l' #UE

#BLENREP ( #GSK) pour les patients atteints de #Myélome R/R

#SARCLISA ( #Sanofi) pour les patients nouvellement diagnostiqués & transplantables

myelom.online/multiples-my...

GSK adds EU to Blenrep checklist as FDA sets new PDUFA date

The #Blenrep saga continues as #GSK secures EMA approval and a new PDUFA date from the FDA for its #multiplemyeloma treatment. pharmaphorum.com/news/gsk-add...

The State of Blenrep: What Patients Should Know - MMRF Updated 7/23/2025 The FDA has announced a delay in its decision on Blenrep (belantamab mafodotin), signaling that more time is needed to complete its review. The deadline for approval is October 23, 2...

The FDA has delayed its decision on Blenrep. The MMRF remains hopeful and continues to support approval. Blenrep offers real potential for patients who need accessible, effective care.

Learn more:
themmrf.org/mmrf-blogs/t...

#MultipleMyeloma #Blenrep #MMRF #FDA

The State of Blenrep: What Patients Should Know - MMRF The MMRF supports FDA approval of Blenrep (belantamab mafodotin) as a meaningful treatment option for patients with relapsed/refractory multiple myeloma. In the coming days, the FDA will decide whethe...

The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep

#FDA advisors have voted that the benefit/#risk profile of #GSK's multiple myeloma therapy, #Blenrep, does not support its approval in the US – denting the prospects of one of the company's top growth products.

pharmaphorum.com/news/gsks-gr...

#gsk #glaxoSmithkline #blenrep #belantamab #mafodotin #blood-cancer #multiple-myeloma #hematologic-cancer #us-fda #fda-panel #drug-approval #drug-safety #advisory-panel #oncology #cancer-treatment #adverse-event-review

#fda #gsk #blenrep #revenue-approval #combination-therapy #blood-cancer #multiple-myeloma #blood-cancer-drug #advisory-panel #drug-approval-process #fda-advisory-panel #us-regulation #oncology #myeloma-treatment #independent-advisers #approved-drug-procedure

The FDA’s ODAC voted against the current benefit-risk profile of #Blenrep. Approval of this novel therapy is still pending.

The MMRF continues to champion safety, equitable access, shared decision-making & team-based care in the development of new #myeloma therapies.

#fda #gsk #blenrep #retra-tuzumab #blood-cancer #eye-safety #ocular-toxicity #drug-safety #drug-combination #cancer-treatment #regulatory-review #clinical-trial #post-market-surveillance #adverse-event #us-fda

Nieuwe ‘paard van Troje’-therapie biedt hoop aan bloedkankerpatiënten in Engeland Key takeaways Duizenden patiënten met bloedkanker in Engeland krijgen als eerste ter wereld toegang tot een baanbrekend geneesmiddel: belantamab mafodotin (Blenrep). Het National Institute for Health and Care Excellence (Nice) gaf onlangs goedkeuring voor deze innovatieve therapie. Hoe Blenrep werkt: het ‘paard van Troje’ tegen kanker Blenrep werkt doelgericht door kankercellen binnen te dringen en […]

Nieuwe ‘paard van Troje’-therapie biedt hoop aan bloedkankerpatiënten in Engeland #Bloedkanker #Kankertherapie #InnovatiefGeneesmiddel #Blenrep #Gezondheidszorg

Une nouvelle thérapie « cheval de Troie » offre de l’espoir aux patients atteints d’un cancer du sang en Angleterre Principaux renseignements Des milliers de patients atteints de cancer du sang en Angleterre bénéficieront d’un médicament révolutionnaire : le belantamab mafodotin (Blenrep). Le National Institute for Health and Care Excellence (NICE) a récemment approuvé cette thérapie innovante. Comment fonctionne Blenrep : le « cheval de Troie » contre le cancer Blenrep agit de façon ciblée. […]

Une nouvelle thérapie « cheval de Troie » offre de l’espoir aux patients atteints d’un cancer du sang en Angleterre #CancerDuSang #ThérapieInnovante #Blenrep #Santé #SoinsDeSanté

NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.

England is the first country in the world to make #GSK's anti-BCMA drug #Blenrep available to patients with the haematological #cancer #multiplemyeloma, in the latest stage of the medicine's renaissance.

Hematology Weekly News – April 21st 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week 🧬 This Week in Hematology: Game-Changing Approvals, Breakthrough Trials & Promising Therapies […] The post Hematology Weekly News – April 21st 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – April 21st 2025 #News #bexmarilimab #Blenrep #CARTtherapy Comment below!

Hematology Weekly News – April 21st 2025 🩸 Hematology Headlines You Shouldn’t Miss This Week 🧬 This Week in Hematology: Game-Changing Approvals, Breakthrough Trials & Promising Therapies […] The post Hematology Weekly News – April 21st 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – April 21st 2025 #News #bexmarilimab #Blenrep #CARTtherapy Comment below!

GSK cements Blenrep comeback with MHRA approval

NEWS: #GSK has secured its first clearance for multiple myeloma drug #Blenrep, marking the beginning of the drug's much-anticipated comeback fuelled by strong trial data.

pharmaphorum.com/news/gsk-cem...